Long-term therapy with sargramostim in a patient with Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 6, 2011, Pages 1447-1448

  Wong, Alan C ^a   Lee, Scott D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MESALAZINE; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; HUMAN; ILEOANAL ANASTOMOSIS; ILEUM; INJECTION SITE REACTION; LETTER; LEUKOCYTE COUNT; LONG TERM CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TOTAL COLON RESECTION; ULCERATIVE COLITIS;

CROHN DISEASE; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MIDDLE AGED;

EID: 79955861626     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21542     Document Type: Letter

References (10)

1. Korzenik JR, Dieckgraefe BK,. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci. 2000; 45: 1121-1129. (Pubitemid 30409456)
2. Hamilton JA,. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008; 8: 533-544. (Pubitemid 351913679)
3. Weisbart RH, Kwan L, Golde DW, et al. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood. 1987; 69: 18-21. (Pubitemid 17007069)
4. Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003; 312: 897-902. (Pubitemid 37492969)
5. Bernasconi E, Favre L, Maillard MH, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010; 16: 428-441.
6. Xu Y, Hunt NH, Bao S,. The role of granulocyte macrophage-colony- stimulating factor in acute intestinal inflammation. Cell Res. 2008; 18: 1220-1229.
7. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005; 352: 2193-2201. (Pubitemid 40727086)
8. Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009; 58: 1354-1362.
9. Feagan BG, Anderson F, Radford-smith GL, et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of N.O.V.E.L. 4, a phase III multicenter study. Gastroenterology. 2007; 132 (Suppl 2): A103.
10. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006; 135: 642-650. (Pubitemid 44674074)